NCT00607841 - A Study of Ispinesib in Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions

Breast Neoplasms

Interventions

DRUG

Ispinesib

10 mg/m2 dose as a 1-hour intravenous infusion.

DRUG

Ispinesib

12 mg/m2 dose as a 1-hour intravenous infusion.

DRUG

Ispinesib

14 mg/m2 dose as a 1-hour intravenous infusion.

Trial Locations (3)

Hospital Nacional Alberto Sabogal Sologúren, Lima

Hospital Nacional Edgardo Rebagliati Martins, Lima

Instituto Nacional de Enfermedades Neoplásicas, Lima